Paladin Healthcare names Henry Loubet CEO

Cara Livernois | | Health Exec | Management

Paladin Healthcare announced that Henry Loubet has been appointed CEO of Paladin Healthcare Alliance.

Loubet will head the new division of Paladin Healthcare responsible for the development of a comprehensive risk-based managed care platform, an affiliated physician alignment strategy and building a community-centric integrated healthcare delivery system to expand equal access to quality healthcare services in underrepresented, disadvantaged communities.

His previous positions include CEO of UnitedHealthcare’s western region, president of Health Net/Foundation Health and director of patient business services and creator of the Valley Health Plan at Santa Clara Valley Medical Center. He also currently serves on the board of directors of Integrated Healthcare Association (IHA), Gem Care Health Plan and MCS IPA.

"I am thrilled to welcome Henry to Paladin and have him serve as CEO of the Paladin Healthcare Alliance. I cannot think of anyone who has the breadth of knowledge, expertise, vision and success that Henry has achieved in the healthcare space,” said Joel Freedman, Paladin’s president. “From his prior experience as CEO of UnitedHealthcare’s Western Region, President of Health Net and Chief Strategy Officer at Keenan, Henry is the ideal leader to guide Paladin Healthcare Alliance in today’s rapidly changing healthcare environment."

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Related Content

Q&A: Proposed changes to Social Security Act would recognize pharmacists as healthcare providers
FDA issues Class I recall on counterfeit infusion pump batteries
FDA issues alert on PCNL sheath safety after patient death
Bipartisan bills in Congress would force insurance companies, PBMs to sell pharmacies
Anthem BCBS reverses course on anesthesia time limits
FDA issues Class I recall on insulin syringes due to risk of death

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.